Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheridan

Showing results (171-180 of 7,540) with videos related to

Pageof 754
Sort By:
Nature Biotechnology|August 8, 2014
Cancer centers zero in on exceptional respondersCormac Sheridan
Nature Biotechnology|April 8, 2016
Exosome cancer diagnostic reaches marketCormac Sheridan
Nature Biotechnology|October 12, 2017
Novartis trial validates inflammasome as chronic disease driverCormac Sheridan
Nature Biotechnology|July 13, 2016
Duchenne muscular dystrophy drugs at the crossroads, as newer agents advanceCormac Sheridan
The American Journal of Gastroenterology|June 1, 1989
Nonrotation of the midgut presenting in the adolescent and adultM Sheridan
Nature Biotechnology|March 11, 2016
Drug developers refocus efforts on RASCormac Sheridan
Nature Biotechnology|September 9, 2015
Omics-driven startups challenge healthcare modelCormac Sheridan
Nature Biotechnology|January 11, 2018
Drugmakers cling to dual IL-13/IL-4 blockbuster hopesCormac Sheridan
Nature Biotechnology|November 8, 2005
The business of making vaccinesCormac Sheridan
Nature Biotechnology|July 9, 2015
Immuno-oncology moves beyond PD-1Cormac Sheridan
Pageof 754

Showing results (171-180 of 7,540) with videos related to

Sort By:
Pageof 754
Nature Biotechnology|August 8, 2014
Cancer centers zero in on exceptional respondersCormac Sheridan
Nature Biotechnology|April 8, 2016
Exosome cancer diagnostic reaches marketCormac Sheridan
Nature Biotechnology|October 12, 2017
Novartis trial validates inflammasome as chronic disease driverCormac Sheridan
Nature Biotechnology|July 13, 2016
Duchenne muscular dystrophy drugs at the crossroads, as newer agents advanceCormac Sheridan
The American Journal of Gastroenterology|June 1, 1989
Nonrotation of the midgut presenting in the adolescent and adultM Sheridan
Nature Biotechnology|March 11, 2016
Drug developers refocus efforts on RASCormac Sheridan
Nature Biotechnology|September 9, 2015
Omics-driven startups challenge healthcare modelCormac Sheridan
Nature Biotechnology|January 11, 2018
Drugmakers cling to dual IL-13/IL-4 blockbuster hopesCormac Sheridan
Nature Biotechnology|November 8, 2005
The business of making vaccinesCormac Sheridan
Nature Biotechnology|July 9, 2015
Immuno-oncology moves beyond PD-1Cormac Sheridan
Pageof 754